Senti Biosciences Holdings, Inc. (SNTI) earnings
SNTI earnings moved a median of -1.95% by the close. Quarterly and annual SNTI reports and results, each read against the price at its own news timestamp. Back to the SNTI overview →
18 measured SNTI earnings events.
Where these SNTI earnings landedvs 18 measured SNTI earnings reactions
| Middle 50% of SNTI earnings reactions | -7.87% to +3.74% |
|---|---|
| Median reaction (to close) | -1.95% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 SNTI earnings events with a measured close landed between -7.87% and +3.74%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase | Press release | +2.80% | +8.00% | |
| Form 10-K/A Senti Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | -4.03% | -6.58% | |
| Form 10-K Senti Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.19% | -8.28% | |
| Form 10-Q Senti Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.82% | -6.67% | |
| Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 | Press release | -1.82% | -6.67% | |
| Form 10-Q Senti Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.26% | +4.08% | |
| Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development | Press release | -0.26% | +4.08% | |
| Form 10-K Senti Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | — | -1.60% | |
| Form 10-Q Senti Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.99% | -12.96% | |
| Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights | Press release | -2.99% | -12.96% | |
| Form 10-Q Senti Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.02% | +9.04% | |
| Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights | Press release | +0.02% | +9.04% | |
| Form 10-Q Senti Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -1.18% | |
| Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights | Press release | +0.00% | -1.18% | |
| Form 10-K/A Senti Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +2.72% | |
| Form 10-K Senti Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -2.29% | |
| Form 10-Q Senti Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.56% | -10.15% | |
| Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates | Press release | +2.56% | -10.15% |
Keep exploring
More SNTI: analyst actions → · SEC filings → · SNTI overview →